Head-To-Head Analysis: Virax Biolabs Group (NASDAQ:VRAX) versus VolitionRx (NYSE:VNRX)

Virax Biolabs Group (NASDAQ:VRAX) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Virax Biolabs Group and VolitionRx’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10,000.00	266.60	-$5.46 million	N/A	N/A
VolitionRx	$770,000.00	71.07	-$35.32 million	($0.46)	-1.43

Virax Biolabs Group has higher earnings, but lower revenue than VolitionRx.

Profitability

This table compares Virax Biolabs Group and VolitionRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
VolitionRx	-4,379.67%	N/A	-150.15%

Insider & Institutional Ownership

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 12.8% of VolitionRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Virax Biolabs Group and VolitionRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	0	0	0	0	N/A
VolitionRx	0	0	1	0	3.00

VolitionRx has a consensus price target of $2.50, suggesting a potential upside of 278.79%. Given VolitionRx’s higher probable upside, analysts plainly believe VolitionRx is more favorable than Virax Biolabs Group.

Volatility & Risk

Virax Biolabs Group has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.

Summary

Virax Biolabs Group beats VolitionRx on 7 of the 10 factors compared between the two stocks.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.